Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Said Q1 Receipts Climb 9 Percent as Net Losses Fall by Half

NEW YORK, May 5 (GenomeWeb News) - Caliper today said that total first-quarter revenues increased 9 percent as net loss declined 51 percent.


Total receipts for the three months ended March 31 increased to $18.4 million from $16.9 million in the similar period of 2004.


Spending on R&D fell to $3.9 million in the quarter from $6.2 million year over year.


Caliper said net loss for the quarter narrowed to $4.9 million, or $.16 per share, from $10 million, or $.35 per share, in the first quarter of 2004.


The company had around $9.9 million in cash and cash equivalents as of March 31.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.